首页> 外文期刊>Bone marrow transplantation >Hospital capacity and post-transplant survival after allogeneic bone marrow transplantation: analysis of data from the Japan Society for Hematopoietic Cell Transplantation.
【24h】

Hospital capacity and post-transplant survival after allogeneic bone marrow transplantation: analysis of data from the Japan Society for Hematopoietic Cell Transplantation.

机译:同种异体骨髓移植后的医院容量和移植后存活:日本造血细胞移植学会的数据分析。

获取原文
获取原文并翻译 | 示例
           

摘要

The association between hospital capacity and survival after allogeneic bone marrow transplantation (allo-BMT) was examined using the dataset accumulated by the Japan Society of Hematopoietic Cell Transplantations (JSHCT). The subjects were 3134 patients who received first allo-BMTs between 1991 and 1997 reported to the JSHCT. They were divided into three groups by cumulative hospital experience of allo-BMTs: low volume (capacity) (LV; < or = 25 cases), moderate volume (capacity) (MV; 26-75 cases) and high volume (capacity) (HV; > or = 76 cases). Using a proportional hazards model, the association of hospital experience with early survival at day 100 (D100S), and overall survival (OS) were examined. For leukemia patients, leukemia-free survival (LFS) was also analyzed. When HV was defined as the reference group, the hazard ratios (HRs) of OS for all subjects were 1.10 (95% confidence interval; 0.97-1.25) for MV and 1.25 for LV (1.08-1.44). The HRs with D100S were 1.20 (0.96-1.51) for MV and 1.40 (1.08-1.80) for LV. Larger values were observed for OS and D100S in cases of leukemia. Survival after BMT from sibling donors was clearly influenced by hospital experience, but this was not the case from unrelated donors. These findings suggest that size of the transplant team should be considered in order to improve the outcome of sibling BMT in general.
机译:使用日本造血细胞移植协会(JSHCT)积累的数据集,检查了同种异体骨髓移植(allo-BMT)后医院容量与生存之间的关联。研究对象为3134名患者,他们在1991年至1997年间接受了JSHCT的首次同种异体BMT治疗。根据同种BMT的累积住院经验将其分为三组:低容量(容量)(LV; <或= 25例),中等容量(容量)(MV; 26-75例)和高容量(容量)( HV;>或= 76例)。使用比例风险模型,检查了医院经验与第100天早期生存率(D100S)和总生存率(OS)的关联。对于白血病患者,还分析了无白血病生存期(LFS)。当将HV定义为参考组时,MV的所有受试者的OS危险比(HRs)为MV的1.10(95%置信区间; 0.97-1.25)和LV(1.08-1.44)的1.25。 D100S的MV的HR为1.20(0.96-1.51),而LV的为1.40(1.08-1.80)。在白血病病例中观察到OS和D100S的值更大。兄弟姐妹捐赠者在接受BMT后的存活率显然受到医院经验的影响,但无关亲戚捐赠者的情况并非如此。这些发现表明,应考虑移植团队的规模,以总体上改善同胞BMT的结局。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号